Wellgistics shares fall 10.44% after-hours as non-binding $105M Neuritek acquisition LOI sparks investor uncertainty.

Wellgistics Health Inc. (NASDAQ: WGRX) fell 10.44% in after-hours trading following the announcement of a non-binding $105 million letter of intent to evaluate the acquisition of Neuritek Therapeutics, a neuroscience-focused research firm. The proposed all-stock deal, if completed, aims to expand Wellgistics’ healthcare platform by integrating Neuritek’s PTSD treatment pipeline. However, the stock decline reflects investor skepticism due to the transaction’s conditional nature—subject to due diligence, board approvals, and financing—which introduces significant uncertainty. The company’s weak financial health, with a $13.75 million market cap and a history of declining share prices, further amplifies concerns about execution risk and potential dilution from an all-stock offer. While the strategic alignment with Neuritek’s innovative therapies could enhance long-term value, the lack of binding commitments and the company’s operational challenges likely drove the bearish reaction.